Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause
Findings provide evidence that HFDD, PROMIS SD SF 8b, and MENQOL scores are valid, reliable and responsive to change, supporting their use for assessing key efficacy endpoints in VMS clinical trials.
Authors
- Christian Seitz (ORCID: https://orcid.org/0000-0003-2315-9148)
- Helena Bradley (ORCID: https://orcid.org/0000-0002-7077-2183)
- Claudia Haberland (ORCID: https://orcid.org/0000-0002-5533-1881)
- Sophie Whyman
- Adam Gater (ORCID: https://orcid.org/0000-0001-9582-8596)
- Asha Lehane (ORCID: https://orcid.org/0000-0003-1689-569X)
- Christoph Gerlinger (ORCID: https://orcid.org/0000-0003-4538-6413)
- Melissa Barclay (ORCID: https://orcid.org/0000-0003-1822-6641)
- Andrew Trigg (ORCID: https://orcid.org/0000-0002-1613-8042)
Institutions
- Adelphi Group (United Kingdom) (GB)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Saarland University (DE)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1186/s41687-025-00875-4
- Citations
- 2
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Bayer